Your browser doesn't support javascript.
loading
SARS-CoV-2 BA.4 infection triggers more cross-reactive neutralizing antibodies than BA.1
Simone Richardson; Thopisang Motlou; Mieke van der Mescht; Bronwen Lambson; Josie Everatt; Daniel Amoako; Anne Van Gottberg; Nicole Wolter; Zelda de Beer; Talita Roma de Villiers; Annie Bodenstein; Gretha van den Berg; Theresa M. Rossouw; Michael Boswell; Veronica Ueckermann; Jinal Bhiman; Penny Moore.
Afiliação
  • Simone Richardson; National Institute for Communicable Diseases of the National Health Laboratory Services, Johannesburg, South Africa
  • Thopisang Motlou; National Institute for Communicable Diseases of the National Health Laboratory Services, Johannesburg, South Africa
  • Mieke van der Mescht; University of Pretoria
  • Bronwen Lambson; National Institute for Communicable Diseases of the National Health Laboratory Services, Johannesburg, South Africa
  • Josie Everatt; National Institute for Communicable Diseases of the National Health Laboratory Services, Johannesburg, South Africa
  • Daniel Amoako; National Institute for Communicable Diseases of the National Health Laboratory Services, Johannesburg, South Africa
  • Anne Van Gottberg; National Institute for Communicable Diseases of the National Health Laboratory Services, Johannesburg, South Africa
  • Nicole Wolter; National Institute for Communicable Diseases of the National Health Laboratory Services, Johannesburg, South Africa
  • Zelda de Beer; University of Pretoria
  • Talita Roma de Villiers; University of Pretoria
  • Annie Bodenstein; University of Pretoria
  • Gretha van den Berg; University of Pretoria
  • Theresa M. Rossouw; University of Pretoria
  • Michael Boswell; University of Pretoria
  • Veronica Ueckermann; University of Pretoria
  • Jinal Bhiman; National Institute for Communicable Diseases of the National Health Laboratory Services, Johannesburg, South Africa
  • Penny Moore; University of the Witwatersrand
Preprint em Inglês | bioRxiv | ID: ppbiorxiv-500039
ABSTRACT
SARS-CoV-2 variants of concern (VOCs) differentially trigger neutralizing antibodies with variable cross-neutralizing capacity. Here we show that unlike SARS-CoV-2 Omicron BA.1, which triggered neutralizing antibodies with limited cross-reactivity, BA.4/5 infection triggers highly cross-reactive neutralizing antibodies. Cross-reactivity was observed both in the absence of prior vaccination and also in breakthrough infections following vaccination. This suggests that next-generation vaccines incorporating BA.4, which is spreading globally, might result in enhanced neutralization breadth.
Licença
cc_by_nc_nd
Texto completo: Disponível Coleções: Preprints Base de dados: bioRxiv Tipo de estudo: Rct Idioma: Inglês Ano de publicação: 2022 Tipo de documento: Preprint
Texto completo: Disponível Coleções: Preprints Base de dados: bioRxiv Tipo de estudo: Rct Idioma: Inglês Ano de publicação: 2022 Tipo de documento: Preprint
...